Woodcock Open To Endpoint Flexibility For Rare Diseases
Executive Summary
Acting US FDA Commissioner also touts master protocols’ potential for rare diseases, arguing patient-funded foundations could overcome sponsor hesitancy to collaborate with potential rivals.
You may also be interested in...
US FDA Open To Innovative Statistical Approaches For Rare Disease
Move over big data, a biostatistician calls for more people to think small for rare diseases and FDA officials indicate openness to the trial approaches laid out.
US FDA Guidance Aims To Tackle Challenges In Multi-Endpoint Trials
Final guidance targets the ‘multiplicity problem.’ At about half the length of the 2017 draft, the final removes some sections, truncates other and drops several examples.
Trials In Focus: FDA Guidance Aims To Tackle Challenges In Multi-Endpoint Trials
Beam Therapeutics also announced that it dosed the first patient in its Phase I/II sickle cell disease trial; Vyne stepped into the increasingly competitive vitiligo space, while Tracon moved further into sarcomas in its checkpoint inhibitor program, and Telix started a small trial of its drug in brain cancer.